Kiniksa Q2 ARCALYST revenue $156.8M (+52% YoY); raises 2025 guidance to $625-640M

Kiniksa Pharmaceuticals International, plc

2025-Q2 EPS reported $0.34 revenue$294,582,000

ARCALYST net product revenue $156.8M in Q2 2025, up 52% from $103.4M in Q2 2024 (excl. $5.2M license revenue).
2025 ARCALYST net revenue guidance raised to $625-640M from prior $590-605M, reflecting continued commercial execution.
Net income of $17.8M in Q2 2025 vs net loss of $3.9M in Q2 2024; cash and investments $307.8M, no debt.
KPL-387 Phase 2/3 trial in recurrent pericarditis recruiting; Phase 2 data expected in 2H 2026.
Approximately 15% of target 14,000 multiple-recurrence pericarditis patients currently on ARCALYST.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.